Fifth Third Bancorp’s Travere Therapeutics TVTX Stock Holding History

Fifth Third Bancorp’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.7K	Buy	1,314 +123	+10%	+$5.45K	﹤0.01%	3077
2026 Q1	$35.4K	Buy	+1,191	New	+$35.6K	﹤0.01%	3322
2025 Q4	–	Sell	-63	Closed	-$1.51K	–	2744
2025 Q3	$1.51K	Buy	+63	New	+$1.18K	﹤0.01%	2486
2019 Q1	–	Sell	-195	Closed	-$4K	–	2307
2018 Q4	$4K	Buy	+195	New	+$4.85K	﹤0.01%	2022
2016 Q4	–	Sell	-450	Closed	-$10K	–	2288
2016 Q3	$10K	Buy	+450	New	+$8.57K	﹤0.01%	1835

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's TVTX Position: Q2 2026 in Review

Fifth Third Bancorp increased its Travere Therapeutics (TVTX) stake by 10% in Q2 2026, buying an estimated $5.45K and bringing the position to 1,314 shares worth $74.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3077.

Fifth Third Bancorp first reported a position in TVTX in Q3 2016 and has held it in 5 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Fifth Third Bancorp held 1,314 shares of Travere Therapeutics worth $74.7K as of Q2 2026.
Fifth Third Bancorp bought 123 Travere Therapeutics shares in Q2 2026, an estimated $5.45K.
Travere Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3077 holding.
Fifth Third Bancorp first reported a position in Travere Therapeutics in Q3 2016 and has held it in 5 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.